Drug Trial Radar · NCT01278394
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
Last checked: Nov 20, 2026Latest source record: Dec 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Mar 2007
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 17, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the safety and efficacy of 5.0% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.
Conditions
- Onychomycosis
Interventions
AN2690 Solution, 5.0%Drug
Once daily application for 360 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360Time frame: Day 360
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Instituto Dermatologico Jalisciense
Guadalajara, Mexico
IMIC
Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.